Therapeutic Nuclease Compositions and Methods
AssigneeUniversity of Washington
InventorsJeffrey A. Ledbetter, Martha Hayden-Ledbetter, Keith Elkon, Xizhang Sun
Life of this patent
Estimating the term…
Abstract
Hybrid nuclease molecules and methods for treating an immune-related disease or disorder in a mammal, and a pharmaceutical composition for treating an immune-related disease in a mammal.
Claims18
A method for degrading circulating RNA and RNA in immune complexes in a subject comprising administering to the subject a composition comprising:
- a polypeptide consisting of
- human RNase 1 operatively coupled with or without a linker to a mutant human IgG1 Fc
- domain, wherein the Fc domain comprises a P238S mutation and a P331S mutation, numbering
- according to the EU index, and wherein the Fc domain does not contain a variable region that
- binds antigen;
- and a pharmaceutically acceptable carrier.
A method of treating discoid LE in a subject comprising administering to the subject a composition comprising:
- a polypeptide consisting of human RNase 1 operatively coupled with or without a linker to a mutant human IgG1 Fc domain, wherein the Fc domain comprises a P238S mutation and a P331S mutation, numbering according to the EU index, and wherein the Fc domain does not contain a variable region that binds antigen;
- and a pharmaceutically acceptable carrier.
A method of making a homodimer, wherein the homodimer comprises a polypeptide consisting of human RNase 1 operatively coupled with or without a linker to a mutant human IgG1 Fc domain, wherein the Fc domain comprises a P238S mutation and a P331S mutation, numbering according to the EU index, and wherein the Fc domain does not contain a variable region that binds antigen;
- and a pharmaceutically acceptable carrier.
Dependencies are inferred from the claim text.